Mankind Pharma gains 10.4% in four sessions as Kotak upgrades stock
Kotak Institutional Equities raised its target price to ₹3,000 from ₹2,885 after Mankind Pharma reported June-quarter revenue growth of 12.9% and net-profit growth of 29.1%. The company is also moving to liquidate BSVL to integrate the subsidiary’s business.
What happened
Mankind Pharma’s shares rose 10.4% in four sessions after Kotak upgraded the stock, citing recovery in its domestic business. The company reported strong
Key facts
- Stock gained 10.4% in four sessions
- Kotak target price raised to ₹3,000 from ₹2,885
- June-quarter revenue ₹4,031 crore, up 12.9%
- June-quarter net profit ₹574 crore, up 29.1%
- EBITDA margin 26.3%, up 250 basis points
What changed
Mankind Pharma’s shares rose 10.4% in four sessions after Kotak upgraded the stock, citing recovery in its domestic business. The company reported strong June-quarter growth and plans to voluntarily liquidate subsidiary BSVL to integrate its business with Mankind.
Why this matters
Kotak’s ₹3,000 target upgrade, alongside a 10.4% four-session rally and 29.1% profit growth, reinforces positive near-term sentiment around Mankind Pharma.
What to watch
- Management guidance on BSVL integration timeline, synergy run-rate and one-off costs.
- Quarterly domestic revenue growth versus the reported 12.9% June-quarter pace.
- Sustained net-profit growth and gross-margin/EBITDA-margin trajectory.
- New product launches, chronic-therapy mix and prescription-market-share data.
- Further broker estimate revisions and whether the share price holds above recent breakout levels.